Guiqiang Zhang

701 citations
41 papers · 568 indexed · h-index 14
Topics
Nanoplatforms for cancer theranostics (18 papers)RNA Interference and Gene Delivery (12 papers)Immunotherapy and Immune Responses (10 papers)
Journals
SHILAP Revista de lepidopterologíaChemistry of MaterialsChemical Communications
Partner nations
ChinaUnited KingdomSudan

In The Last Decade

Guiqiang Zhang

38 papers receiving 559 citations

Peers

Guiqiang Zhang
Comparison fields: 5 of 108
  • Molecular Biology 188
  • Biomedical Engineering 176
  • Immunology 120
  • Biomaterials 85
  • Artificial Intelligence 68
Replace Wenwen Xu with:
Wenwen Xu China
Xinyi Zhang China
Chunhui Li China
Dejun Sun China
Somayeh Sadeghi Iran
Jiewen Wang China
Hyungu Kang South Korea
Qiqi Yu China
Guiqiang Zhang relative to Wenwen Xu China Wenwen Xu's profile →
Citations per field
00.5×1.5×
Wenwen Xu · 1×
Citations per year

Countries citing papers authored by Guiqiang Zhang

Since Specialization
Citations

This map shows the geographic impact of Guiqiang Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guiqiang Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guiqiang Zhang more than expected).

Fields of papers citing papers by Guiqiang Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guiqiang Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guiqiang Zhang. The network helps show where Guiqiang Zhang may publish in the future.

Co-authorship network of co-authors of Guiqiang Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Guiqiang Zhang. A scholar is included among the top collaborators of Guiqiang Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guiqiang Zhang. Guiqiang Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 2
3 6
4 0
5 0
6 1
7 10
8 4
9 23
10 1
11 5
12 4
13 4
14 18
15 18
16 10
17 4
18 18
19 35
20 6

About Guiqiang Zhang

Guiqiang Zhang is a scholar working on Immunology, Biomaterials and Biomedical Engineering, having authored 41 papers that have together received 568 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (18 papers), RNA Interference and Gene Delivery (12 papers) and Immunotherapy and Immune Responses (10 papers). The work is most often cited by research in Biomaterials (85 citations), Immunology (120 citations) and Pharmaceutical Science (27 citations). Guiqiang Zhang has collaborated with scholars based in China, United Kingdom and Sudan. Frequent co-authors include Jiwei Cui, Haifeng Sun, Shuxia Lu, Xizhao Wang, Xu Zhou, Xiao Fu, Shumei Zhai, Jingcheng Hao, Tao Hu and Hongtao Liu. Their work appears in journals such as SHILAP Revista de lepidopterología, Chemistry of Materials and Chemical Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026